SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77844.52
114 (-0.15%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Abbott India Ltd.	Q V PT	55,876 Mid Cap	26,692.15 (1.51%)	36.66	12.74	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Neuland Laboratories Ltd.	Q V+ PT	21,775 Small Cap	17,300.45 (1.94%)	122.11	13.18	14.13	64.99	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Astrazeneca Pharma India Ltd.	Q V+ PT	20,924 Small Cap	8,535.30 (1.98%)	104.15	25.16	15.59	20.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,11,527 Large Cap	7,837.85 (1.05%)	77.25	11.5	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Divis Laboratories Ltd.	Q V+ PT	1,78,026 Large Cap	6,700.75 (-0.08%)	71.81	11.13	11.65	10.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Kovai Medical Center & Hospital Ltd.	Q V+ PT	6,253 Small Cap	5,757.45 (0.76%)	26.52	4.98	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Alkem Laboratories Ltd.	Q V+ PT	66,240 Mid Cap	5,590.85 (0.92%)	30.19	4.64	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Procter & Gamble Health Ltd.	Q V PT	8,854 Small Cap	5,314.25 (-0.37%)	30.17	12.7	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,470 Small Cap	5,063.95 (-0.90%)	35.36	7.44	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,728 Small Cap	4,759.55 (2.18%)	41.6	23.74	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Pfizer Ltd.	Q V PT	21,876 Small Cap	4,749.60 (-0.67%)	25.63	5.48	1.18	5.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,47,478 Large Cap	4,358.95 (0.03%)	64.91	16.23	7.72	15.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Sanofi India Ltd.	Q V PT	7,823 Small Cap	3,392.35 (-0.14%)	25.25	10.03	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Ajanta Pharma Ltd.	Q V PT	38,646 Small Cap	3,080.20 (-0.42%)	36.6	8.54	12.43	17.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Acutaas Chemicals Ltd.	Q V+ PT	21,963 Small Cap	2,721.70 (1.46%)	59.98	13.16	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	RPG Life Sciences Ltd.	Q V+ PT	3,946 Small Cap	2,480.95 (3.98%)	34.27	6.52	11.71	30.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	41,069 Mid Cap	2,478.95 (2.25%)	40.22	20.5	3.06	33.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Lupin Ltd.	Q V+ PT	1,11,668 Mid Cap	2,459.75 (0.71%)	24.04	5.37	8.11	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Mankind Pharma Ltd.	Q V PT	97,506 Mid Cap	2,375.40 (0.57%)	57.24	6.11	14.65	12.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Glenmark Pharmaceuticals Ltd.	Q V+ PT	66,987 Mid Cap	2,371.05 (-0.11%)	62.89	6.71	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	JB Chemicals & Pharmaceuticals Ltd.	Q V+ PT	34,370 Small Cap	2,141.35 (0.03%)	47.25	8.81	17.81	19.45	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Gland Pharma Ltd.	Q V PT	29,863 Small Cap	1,871.20 (3.24%)	25.54	2.88	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Caplin Point Laboratories Ltd.	Q V PT	13,982 Small Cap	1,866.20 (1.45%)	22.78	4.2	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Narayana Hrudayalaya Ltd.	Q V+ PT	37,598 Mid Cap	1,862.10 (1.21%)	48.27	8.97	11.88	45.85	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,43,973 Large Cap	1,834.40 (-0.86%)	40.67	5.47	9.87	23.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Onesource Specialty Pharma Ltd.	Q V PT	19,979 Small Cap	1,816.55 (4.24%)	114.42	3.37	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	CORONA Remedies Ltd.	Q V+ PT	10,682 Small Cap	1,738.30 (-0.48%)	71.67	15.25	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Kwality Pharmaceuticals Ltd.	Q V+ PT	1,791 Small Cap	1,715.30 (-0.62%)	31.67	5.83	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Poly Medicure Ltd.	Q V PT	16,787 Small Cap	1,679.50 (1.41%)	49.08	5.66	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Emcure Pharmaceuticals Ltd.	Q V PT	31,472 Small Cap	1,662.90 (0.17%)	42.94	8.48	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Piramal Pharma	183.85	11.36%
Indoco Remedies	251.25	10.22%
Nectar Lifesciences	13.59	9.95%
Sun Pharma Adv. Res	166.95	6.30%
Guj. Kidney & Super	130.90	6.03%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Wockhardt	1,636.75	-4.85%
Rubicon Research	951.90	-4.72%
Wanbury	252	-2.25%
Concord Biotech	1,197.15	-2.12%
Aarti Pharmalabs	776.60	-1.51%

News about Top Pharma Companies in India

May, 2026

Ajanta Pharma - Quaterly Results

The Revenue for the quarter ended March 2026 of Rs. 12105.30 millions grew by 19.39 % from Rs. 10139.40 millions.Net profit showed a marginal rise at Rs. 1972.80 millions for the quarter ended March 2026, as compared to corresponding quarter of last year.Operating profit surged to 3010.30 millions from the corresponding previous quarter of 2675.80 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	12105.30	10139.40	19.39	48459.20	43220.40	12.12	48459.20	43220.40	12.12
Other Income	629.80	179.30	251.25	2044.00	1198.70	70.52	2044.00	1198.70	70.52
PBIDT	3010.30	2675.80	12.50	14023.90	13245.90	5.87	14023.90	13245.90	5.87
Interest	-7.40	6.70	-210.45	25.90	46.00	-43.70	25.90	46.00	-43.70
PBDT	3017.70	2669.10	13.06	13998.00	13199.90	6.05	13998.00	13199.90	6.05
Depreciation	441.60	387.60	13.93	1687.70	1399.30	20.61	1687.70	1399.30	20.61
PBT	2576.10	2281.50	12.91	12310.30	11800.60	4.32	12310.30	11800.60	4.32
TAX	603.30	347.20	73.76	2842.10	2631.70	7.99	2842.10	2631.70	7.99
Deferred Tax	-70.00	-43.80	59.82	76.00	51.40	47.86	76.00	51.40	47.86
PAT	1972.80	1934.30	1.99	9468.20	9168.90	3.26	9468.20	9168.90	3.26
Equity	250.70	250.70	0.00	250.70	250.70	0.00	250.70	250.70	0.00
PBIDTM(%)	24.87	26.39	-5.77	28.94	30.65	-5.57	28.94	30.65	-5.57

May, 2026

Emcure Pharma - Quaterly Results

A fair growth of 14.83% in the revenue at Rs. 14677.03 millions was reported in the March 2026 quarter as compared to Rs. 12781.88 millions during year-ago period.Net profit surges 67.46% to Rs. 2336.97 millions from Rs. 1395.57 millions in the quarter ended March 2026.The company reported a good operating profit of 3985.94 millions compared to 2670.33 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202603	202503	% Var	202603	202503	% Var	202603	202503	% Var
Sales	14677.03	12781.88	14.83	52431.88	43819.24	19.65	52431.88	43819.24	19.65
Other Income	269.39	223.96	20.28	2095.16	1188.07	76.35	2095.16	1188.07	76.35
PBIDT	3985.94	2670.33	49.27	13342.66	7656.44	74.27	13342.66	7656.44	74.27
Interest	368.67	240.69	53.17	1182.71	1129.62	4.70	1182.71	1129.62	4.70
PBDT	3693.06	2429.64	52.00	11909.24	6526.82	82.47	11909.24	6526.82	82.47
Depreciation	630.40	569.12	10.77	2467.33	2249.72	9.67	2467.33	2249.72	9.67
PBT	3062.66	1860.52	64.61	9441.91	4277.10	120.75	9441.91	4277.10	120.75
TAX	725.69	464.95	56.08	2112.32	1105.82	91.02	2112.32	1105.82	91.02
Deferred Tax	-62.93	-170.95	-63.19	-225.09	-21.25	959.25	-225.09	-21.25	959.25
PAT	2336.97	1395.57	67.46	7329.59	3171.28	131.12	7329.59	3171.28	131.12
Equity	1895.90	1894.83	0.06	1895.90	1894.83	0.06	1895.90	1894.83	0.06
PBIDTM(%)	27.16	20.89	29.99	25.45	17.47	45.64	25.45	17.47	45.64

May, 2026

Emcure Pharmaceuticals informs about change in management

Pursuant to Regulation 30 of the SEBI Listing Regulations and based on the recommendation of the Nomination and Remuneration Committee, Emcure Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 05, 2026, has approved the re-appointment of the following Directors, subject to approval of shareholders: 1. Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of 1 (One) year commencing from August 28, 2026; 2. Satish Mehta (DIN: 00118691) as the Managing Director of the Company, for a further period of 5 (Five) years with effective from April 01, 2027. Dr. Mukund Gurjar and Satish Mehta are not debarred from holding the office of a Director by virtue of any Securities and Exchange Board of India (‘SEBI’) SEBI order and in accordance with BSE Circular No. LIST/COMP/14/2018-19 dated June 20, 2018 and NSE Circular No. NSE/CML/2018/02 dated June 20, 2018, or any such other authority, and that they are not related to any Director(s) or Key Managerial Personnel(s) of the Company. The particulars of the disclosure required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations are enclosed. The meeting of the Board of Directors of the Company commenced at 12.42 pm (IST) and concluded at 2.00 pm (IST).

The above information is a part of company’s filings submitted to BSE.

May, 2026

Sanofi Consumer Healthcare India informs about disclosures

Sanofi Consumer Healthcare India has informed that the Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nippon India Mutual Fund.

The above information is a part of company’s filings submitted to BSE.

May, 2026

Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia

May, 2026

Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection

Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Abbott India Ltd.	55,876 Crore
2	Neuland Laboratories Ltd.	21,775 Crore
3	Astrazeneca Pharma India Ltd.	20,924 Crore
4	Apollo Hospitals Enterprise Ltd.	1,11,527 Crore
5	Divis Laboratories Ltd.	1,78,026 Crore
6	Kovai Medical Center & Hospital Ltd.	6,253 Crore
7	Alkem Laboratories Ltd.	66,240 Crore
8	Procter & Gamble Health Ltd.	8,854 Crore
9	Dr Agarwals Eye Hospital Ltd.	2,470 Crore
10	Sanofi Consumer Healthcare India Ltd.	10,728 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,692	55,876	36.66	12.74	25.65	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,359	1,47,478	64.91	16.23	36.68	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,080	38,646	36.60	8.54	24.73	24.45
Lupin Ltd. (M)	Somewhat Good	2,460	1,11,668	24.04	5.37	14.31	20.83
Zydus Lifesciences Ltd. (M)	Very Good	940	94,495	19.13	3.60	11.92	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,206	63,517	92.14
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,371	66,987	68.93
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,141	34,370	42.38
Wockhardt Ltd. (S)	Not Good	1,637	27,953	39.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,359	1,47,478	33.30
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,141	34,370	47.25	8.81	29.84	17.81
Mankind Pharma Ltd. (M)	Very Good	2,375	97,506	57.24	6.11	34.36	14.65
Laurus Labs Ltd. (M)	Very Good	1,206	63,517	71.46	11.98	35.90	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,307	1,09,382	19.64	2.94	11.80	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,080	38,646	36.60	8.54	24.73	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	940	94,495	19.13	3.60	11.92	30.57
Cipla Ltd. (L)	Very Good	1,363	1,10,283	24.26	3.28	14.63	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,834	4,43,973	40.67	5.47	22.24	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,307	1,09,382	19.64	2.94	11.80	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,141	34,370	47.25	8.81	29.84	19.45

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Ajanta Pharma - Quaterly Results

Emcure Pharma - Quaterly Results

Emcure Pharmaceuticals informs about change in management

Sanofi Consumer Healthcare India informs about disclosures

Caplin Point gains as its arm gets USFDA’s approval for Calcium Gluconate Injection

Caplin Point’s arm gets USFDA’s approval for Calcium Gluconate Injection

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.